FDA Grants Mirvetuximab Full Approval for Ovarian Cancer

Mirvetuximab soravtansine-gynx (Elahere) is approved for patients with folate receptor–alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Medscape Medical News

source https://www.medscape.com/viewarticle/fda-grants-mirvetuximab-full-approval-ovarian-cancer-2024a10005m0?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost